Clinical Trials

18 enrolled

Neoplasms

NCT05571969 2025-05-07

Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors

40 enrolled

Advanced Solid Tumors

NCT05191667 2025-02-13

AN0025 and Chemoradiotherapy Combination in Esophageal Cancer

32 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT04120246 2024-07-10

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

24 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04714983 2024-04-09

DNX-2440 for Resectable Colorectal Liver Metastasis

BreastDermatologicGastrointestinalGenitourinarySarcoma

30 enrolled

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Melanoma, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT03932253 2024-03-27

MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)

79 enrolled

Dermatologic

Melanoma

NCT04711161 2024-01-23

First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

73 enrolled

Gynecologic

Ovarian Neoplasms

NCT04996030 2024-01-23

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

Other hematologic neoplasm

16 enrolled

Leukemia, Promyelocytic, Acute

NCT04053062 2024-01-05

LIGHT-PSMA-CART in Treating Patients With Castrate-Resistant Prostate Cancer

12 enrolled

Genitourinary

Castrate-Resistant Prostate Cancer

NCT03859752 2023-09-22

TR1801-ADC in Patients With Tumors That Express c-Met

15 enrolled

Unspecified Adult Solid Tumor, Protocol Specific

NCT04650451 2023-04-20

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

220 enrolled

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT03970382 2022-08-18

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

21 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Melanoma, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03722186 2021-03-22

Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies

LymphoidOther hematologic neoplasm

128 enrolled

Lymphoma, Neoplasms by Histologic Type, Hematologic Neoplasms

NCT03120130 2019-10-14

Amblyomin-X

24 enrolled

Advanced Cancer

NCT02093871 2017-07-21

PISH-2

20 enrolled

Gynecologic

Hyperthermia, Ovarian Neoplasms

NCT01762410 2014-09-29

Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors

60 enrolled

Advanced Refractory Solid Tumors

NCT01779336 2014-09-29

Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors

70 enrolled

Advanced Refractory Solid Tumors

NCT01841463 2014-09-04

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

100 enrolled

Dermatologic

Melanoma

NCT02117336 2014-09-03

Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

LymphoidOther hematologic neoplasm

36 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01337518 2012-12-18

A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer

150 enrolled

Genitourinary

Adenocarcinoma, Neoplasm Metastasis, Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT01604863 2012-11-01

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

GenitourinaryOther solid neoplasmThoracic

54 enrolled

Lung Neoplasms, Mesothelioma, Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT00909558 2010-02-24

Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer

BreastCNSGastrointestinalGenitourinary

24 enrolled

Breast Neoplasms, Colonic Neoplasms, Glioma, Liver Neoplasms, Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT00459823 2009-03-24

A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours

40 enrolled

Neoplasms

NCT00827203 2009-03-09

A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors

30 enrolled

Neoplasm Metastasis, Neoplasms

NCT00499499 2009-02-04

A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors

40 enrolled

Neoplasms

NCT00264472 2008-12-15

A Study of 5 Fluorouracil and the Anti-Tumor Activity of ADH300004 and 5 Fluorouracil in Subjects With Incurable Solid Tumors

60 enrolled

Neoplasms

NCT00753480 2008-11-07

A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

56 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00460278 2008-06-04

Study of XL418 in Adults With Solid Tumors

63 enrolled

Neoplasms

NCT00607711 2008-05-05

Study of Oral Palifosfamide Tris in Solid Tumors

20 enrolled

Advanced Cancer

NCT00591682 2008-03-26

MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

27 enrolled

Solid Tumors

NCT00077493 2007-12-28

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma